Cancer chemoprevention with dietary isothiocyanates mature for clinical translational research

Shivendra V. Singh1,2,4 and Kamayani Singh2

1Department of Pharmacology and Chemical Biology and 2University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA

*To whom correspondence should be addressed. Tel: +1 412 623 3263; Fax: +1 412 623 7828; E-mail: singhsv@upmc.edu

Inverse association between dietary intake of cruciferous vegetables and cancer risk observed in population-based case-control studies is partly attributable to structurally simple but mechanistically complex phytochemicals with an isothiocyanate (−N=C=S) functional group. Cancer protective role for dietary isothiocyanates (ITCs) is substantiated by preclinical studies in rodent models. A common feature of many naturally occurring ITCs relates to their ability to cause growth arrest and cell death selectively in cancer cells. At the same time, evidence continues to accumulate to suggest that even subtle change in chemical structure of the ITCs can have a profound effect on their activity and mechanism of action. Existing mechanistic paradigm stipulates that ITCs may not only prevent cancer initiation by altering carcinogen metabolism but also inhibit post-initiation cancer development by suppressing many processes relevant to tumor progression, including cellular proliferation, neoangiogenesis, epithelial–mesenchymal transition, and self-renewal of cancer stem cells. Moreover, the ITCs are known to suppress diverse oncogenic signaling pathways often hyperactive in human cancers (e.g. nuclear factor-κB, hormone receptors, signal transducer and activator of transcription 3) to elicit cancer chemopreventive response. However, more recent studies highlight potential adverse effect of Notch activation by ITCs on their ability to inhibit migration of cancer cells. Mechanisms underlying ITC-mediated modulation of carcinogen metabolism, growth arrest, and cell death have been reviewed extensively. This article provides a perspective on bench-cage-bedside evidence supporting cancer chemopreventive role for some of the most promising ITCs. Structure–activity relationship and mechanistic complexity in the context of cancer chemoprevention with ITCs is also highlighted.

Introduction

Social and economic burden from cancer is still quite substantial around the world despite increasing awareness of life-style risk factors (e.g. smoking) and screening efforts for early detection of the disease. Novel approaches for prevention of cancer are desirable mainly because many risk factors associated with tumor development are not easily modifiable (e.g. genetic predisposition). Chemoprevention of cancer is feasible as exemplified by selective estrogen receptor modulators and aromatase inhibitors for breast cancer risk reduction (1–3). Chemopreventive role for some of the most promising ITCs, including watercress constituent phenethyl isothiocyanate (PEITC), garden cress constituent benzyl isothiocyanate (BITC) and synthetic racemic analogue of broccoli constituent l-sulforaphane (l-t.-sulforaphane; hereafter abbreviated as SFN) (4–6). Chemical structures of BITC, PEITC and SFN are shown in Figure 1.

The ITCs are stored as thiolglucoside conjugates (commonly known as glucosinolates) in cruciferous vegetables (7,8). For example, the glucosinolate precursor of PEITC is glucoraphanin, whereas l-sulforaphane is stored as glucoraphain in cruciferous vegetables (8). Plant tissue damage resulting from cutting or chewing of the cruciferous vegetables releases an enzyme (myrosinase) that is responsible for conversion of the glucosinolates to corresponding ITCs (8). The ITCs can also be generated by intestinal microflora (9). Substantial amounts of glucosinolates are achievable through dietary intake of the cruciferous vegetables. For example, glucosinolate content in edible cruciferous vegetables ranges from 0.5 to 3 mg/g and one ounce of watercress is estimated to result in intake of about 37 μmol of PEITC (10).

ITCs are effective inhibitors of chemically induced cancer in experimental rodents

Wattenberg was the first to report inhibition of chemically induced cancer in experimental rodents upon PEITC and BITC administration more than 30 years ago (11). Specifically, the PEITC administration 4 hours before 7,12-dimethylbenz[a]anthracene administration resulted in inhibition of mammary carcinogenesis in rats (11). Since then, a number of studies from different laboratories have documented protective effect of PEITC and BITC against cancer in rodents induced by structurally diverse chemical carcinogens. In this context, contributions of Gary D. Stoner, Late Bandaru S. Reddy, Stephen S. Hecht, Fung-Lung Chung, and Paul Talalay et al. are noteworthy (10,12–15). Some of their seminal studies documenting ITC-mediated prevention of chemically induced cancers are summarized in Table I and exemplified later.

Stoner group showed that the rats fed a diet supplemented with 3 and 6 mmol PEITC/kg diet before (pre-initiation) as well as during treatment with the carcinogen N-nitrosobenzylmethyamine (post-initiation) developed significantly fewer esophageal tumors compared with rats fed a control diet (12). Lung tumorigenesis induced by the tobacco-derived carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butaneone in rats was inhibited significantly by dietary administration of 4 and 8 mmol PEITC/kg diet (13). Gavage of PEITC inhibited azoxymethane-induced colonic aberrant crypt foci in rats providing important laboratory evidence for protection against colon cancer (15). Feeding of diet supplemented with

Abbreviations: BITC; benzyl isothiocyanate; EMT, epithelial to mesenchymal transition; ITCs, isothiocyanates; PEITC, phenethyl isothiocyanate; ROS, reactive oxygen species; SFN, l-t.-sulforaphane; TRAMP, transgenic adenocarcinoma of mouse prostate.

© The Author 2012. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com

Advance Access Publication June 27, 2012

Carcinogenesis vol.33 no.10 pp.1833–1842, 2012

Fig. 1. Chemical structure of phenethyl isothiocyanate (PEITC), benzyl isothiocyanate (BITC), and sulforaphane (SFN).

© This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License which allows any non-commercial use and distribution of the work without further permission provided the original work is properly cited.
0.05% PEITC before or after azoxymethane initiation resulted in lower tumor incidence, lower colon tumor multiplicities and smaller polyps, as compared with mice fed with the basal diet (16). Notably, Plate and Gallaher (17) failed to observe PEITC-mediated prevention of aberrant crypt foci in rats. Yang et al. (18) showed inhibition of benzo(a)pyrene-induced lung tumorigenesis in A/J mice by dietary N-acetylcyesteine conjugate of PEITC administered during the post-initiation phase. PEITC administration was also shown to suppress N-nitrosomethylbenzylamine-induced hamster buccal pouch cancer (19). Similar to PEITC, cancer protective role for BITC has been demonstrated in a number of chemically induced rodent cancer models, including 7,12-dimethylbenz[a]anthracene-induced breast cancer and benzo[a]pyrene-induced forestomach cancer and pulmonary adenoma using rats or mice (20–23), diethylnitrosamine-induced forestomach tumor in mice (23), methylazoxymethanol acetate-induced intestinal carcinogenesis in rats (24), 5-methylcytosine and dibenz(a,h)anthracene-induced lung cancer in mice (25), diethylnitrosamine-induced liver cancer in rats (26), and N-nitrosobis(2-oxopropyl)amine-induced pancreatic atypical hyperplasia and adenocarcinoma in hamsters (27).

Talalay et al. are credited with sparking research interest in SFN by demonstrating preventive activity against 9,10-dimethyl-1,2-benzanthracene-induced breast cancer in rats (14). Subsequently, chemopreventive response to SFN was extended to other chemical carcinogens. For example, both pre- and post-initiation administration of SFN resulted in suppression of colonic aberrant crypt foci in rats induced by azoxymethane (28). However, SFN–N-acetylcysteine conjugate exhibited activity only against post-initiation cancer development (28). SFN-mediated inhibition of benzo[a]pyrene-induced forestomach cancer in mice has also been demonstrated (29). SFN and its N-acetylcysteine conjugate inhibited malignant progression of lung adenomas induced by tobacco carcinogens in A/J mice (30). SFN treatment was shown to prevent chemically induced skin cancer during the stage of promotion (31). It is important to mention that some studies have used the naturally occurring L-isomer whereas others have utilized synthetic racemic compound in these studies (14,28–31). Nevertheless, it is now obvious that ITCs can offer protection against cancer in experimental rodents induced by structurally diverse chemical carcinogens.

### Table I. Protective effect of isothiocyanates (ITCs) against chemically-induced cancer in rodents

<table>
<thead>
<tr>
<th>Compound</th>
<th>Activity</th>
<th>Carcinogen</th>
<th>Rodent species</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEITC</td>
<td>Inhibition of mammary carcinogenesis</td>
<td>DMBA</td>
<td>Female Sprague-Dawley rat</td>
<td>(11)</td>
</tr>
<tr>
<td></td>
<td>Inhibition of esophageal tumorigenesis</td>
<td>NBMA</td>
<td>Male F344 rat</td>
<td>(12)</td>
</tr>
<tr>
<td></td>
<td>Inhibition of lung tumorigenesis</td>
<td>NKK</td>
<td>Male F344 rat</td>
<td>(13)</td>
</tr>
<tr>
<td></td>
<td>Inhibition of aberrant crypt foci formation</td>
<td>AOM</td>
<td>Male F344 rat</td>
<td>(28)</td>
</tr>
<tr>
<td></td>
<td>Inhibition of colon tumor multiplicity</td>
<td>AOM/DSS</td>
<td>Male C57BL/6 mice</td>
<td>(16)</td>
</tr>
<tr>
<td></td>
<td>Inhibition of oral squamous epithelial carcinogenesis</td>
<td>NBMA</td>
<td>Male Syrian golden hamster</td>
<td>(19)</td>
</tr>
<tr>
<td></td>
<td>Inhibition of neoplasia of the forestomach</td>
<td>BaP</td>
<td>A/J mouse</td>
<td>(21)</td>
</tr>
<tr>
<td></td>
<td>Inhibition of lung tumor multiplicity</td>
<td>BaP+NNK</td>
<td>A/J mouse</td>
<td>(22)</td>
</tr>
<tr>
<td></td>
<td>Inhibition of lung tumorigenesis</td>
<td>BaP</td>
<td>A/J mouse</td>
<td>(18)</td>
</tr>
<tr>
<td>PEITC-NAC</td>
<td>Inhibition of mammary carcinogenesis</td>
<td>DMBA</td>
<td>Female Sprague-Dawley rat</td>
<td>(11)</td>
</tr>
<tr>
<td></td>
<td>Inhibition of neoplasia of the breast</td>
<td>DMBA</td>
<td>Female Sprague-Dawley rat</td>
<td>(20)</td>
</tr>
<tr>
<td>BITC</td>
<td>Inhibition of neoplasia of the breast</td>
<td>DMBA</td>
<td>Female Sprague-Dawley rat</td>
<td>(20)</td>
</tr>
<tr>
<td></td>
<td>Inhibition of intestinal carcinogenesis</td>
<td>MAM acetate</td>
<td>Female ACI/N rat</td>
<td>(24)</td>
</tr>
<tr>
<td></td>
<td>Inhibition of lung tumorigenesis</td>
<td>5-MeC+DBahA</td>
<td>A/J mouse</td>
<td>(25)</td>
</tr>
<tr>
<td></td>
<td>Inhibition of liver tumorigenesis</td>
<td>DEN</td>
<td>Female A/J mouse</td>
<td>(23)</td>
</tr>
<tr>
<td>SFN</td>
<td>Inhibition of pancreas carcinogenesis</td>
<td>DEN</td>
<td>Male A/J mouse</td>
<td>(23)</td>
</tr>
<tr>
<td></td>
<td>Inhibition of colon cancer</td>
<td>DEN</td>
<td>Male A/J mouse</td>
<td>(23)</td>
</tr>
<tr>
<td></td>
<td>Inhibition of neoplasia of the forestomach</td>
<td>DEN</td>
<td>Male Syrian hamster</td>
<td>(27)</td>
</tr>
<tr>
<td></td>
<td>Inhibition of neoplasia of the forestomach</td>
<td>DEN</td>
<td>Male Syrian hamster</td>
<td>(27)</td>
</tr>
<tr>
<td></td>
<td>Inhibition of skin tumor multiplicity</td>
<td>DEN</td>
<td>Male Syrian hamster</td>
<td>(27)</td>
</tr>
</tbody>
</table>

### Abbreviations: PEITC, phenethyl isothiocyanate; PEITC-NAC, N-acetylcysteine conjugate of PEITC; BITC, benzyl isothiocyanate; SFN, sulforaphane; DMBA, 7,12-dimethylbenz[a]anthracene; NBMA, N-nitrosobenzylmethyamine; NKK, 4-(methyltrisamino)-1-(3-pyridyl)-1-butaneone; AOM, azoxymethane; DSS, dextran sodium sulfate; BaP, benzo[a]pyrene; DEN, diethylnitrosamine; MAM acetate, methylazoxymethanol acetate; 5-MeC, 5-methylchrysene; DBahA, dibenz[a,h]anthracene; BOP, N-nitrosobis(2-oxopropyl)amine; TPA, 12-O-tetradecanoylphorbol 13-acetate

### Bladder carcinogenesis/promotion in rats is concerning for some ITCs

A few studies, albeit inconsistently, have suggested that some ITCs might act as a bladder carcinogen or promote chemically induced bladder tumorigenesis at least in rats. Using a rather complex multigorgan carcinogenesis model in rats involving a single intraperitoneal injection of diethylnitrosamine, 4 intraperitoneal injections of N-nitroisourea as well as N-butyl-N-(4-hydroxybutyl)nitrosamine administration in the drinking water during the first 2 weeks followed by 4 subcutaneous injections of dimethylhydrazine as well as 2,2’-dihydroxy-di-n-propylentrosamine in the drinking water over 2 weeks, PEITC administration lowered the induction of esophageal hyperplasia, kidney atypical tubules, and liver glutathione S-transferase placental form-positive foci when given during the initial period but enhanced the development of liver glutathione S-transferase placental form-positive foci and urinary bladder tumors if administered in the post-initiation period (32). Additional work from this same group showed that PEITC-induced papillary or nodular hyperplasia, dysplasia, and transitional cell carcinoma in a dose-dependent manner but only after initiation with diethylnitrosamine and N-butyl-N-(4-hydroxybutyl)nitrosamine (33). Whether PEITC alone acts as a carcinogen in the urinary bladder is also controversial. Some studies indicate that PEITC can promote proliferation in normal looking epithelium leading to dysplasia (34). Other studies indicated that PEITC treatment had only limited potential to initiate abnormal growth and did not effectively induce irreversible lesion in urinary bladder (35). Similar inconsistencies are discernible for BITC in the context of bladder cancer in rats. In experiments designed to determine the post-initiation effect of BITC against hepatocarcinogenesis and urinary bladder carcinogenesis, rats were pretreated with diethylnitrosamine and N-butyl-N-(4-hydroxybutyl)nitrosamine prior to dietary BITC administration (36). Incidence of papillary or nodular hyperplasia and carcinoma were significantly elevated in the BITC treatment group (36). Interestingly, BITC potentely inhibited induction of these lesions when given simultaneously with the carcinogen (37). In a follow-up study, simultaneous treatment with BITC and a lower dose of the same carcinogen did not inhibit, but rather enhanced rat urinary bladder carcinogenesis (38).
These observations will undoubtedly pose difficulties in regulatory approval of PEITC or BITC as a potential chemopreventive agent for long-term administration in high-risk but otherwise normal healthy subjects. At the same time, a few arguments lend support for long-term administration of these agents for cancer chemoprevention purpose. First, bladder carcinogenesis or promotion of chemically induced bladder cancer by PEITC or BITC has not been reported in any other rodent species (e.g. mouse). Second, PEITC/BITC-containing cruciferous vegetables are consumed by humans on a daily basis in some cultures, yet epidemiological studies have suggested an inverse association between intake of these vegetables and bladder cancer risk and survival (39–41). It is possible that rats are unusually sensitive to bladder carcinogenesis by PEITC and BITC. Finally, human relevance of the multigorgan rat carcinogenesis models employed to demonstrate bladder tumor promoting effects of PEITC and BITC (32,36) is unclear if not questionable. Notably, at least two studies have documented clastogenic effects of BITC (42,43). Furthermore, BITC treatment exhibited genotoxic effects in HepG2 cells but substantially weaker effects were obtained in vivo (44). Clearly, toxicological evaluations after long-term administration of PEITC and BITC in different species are needed to advance these agents into clinical translational studies.

Bladder carcinogenesis or promotion of chemically induced bladder cancer has not been reported for SFN. In fact, a recent study showed that SFN administration inhibited DNA adduct formation induced by a bladder carcinogen, 4-aminobiphenyl, in a NF-E2 related factor-2-dependent manner in bladder cells and tissues (45). Furthermore, dietary administration of a freeze-dried aqueous extract of broccoli sprouts, which is a rich source of glucoraphanin, conferred significant and dose-dependent protection against bladder cancer development in rats induced by N-butyl-N-(4-hydroxybutyl) nitrosamine (46). It is important to note that the broccoli sprout extract itself did not cause any histologic changes in the bladder (46).

ITCs prevent oncogene-driven cancer development in transgenic mice

Availability of transgenic mouse models in recent years has enabled determination of chemopreventive efficacy of the ITCs against spontaneous cancer development. Key studies documenting cancer chemoprevention by ITCs in transgenic mouse models are summarized in Table II. For example, the Apc\textsuperscript{Min} mice fed a diet supplemented with 0.05% PEITC for 3 weeks developed significantly less (31.7% reduction) and smaller polyps than those fed basal diet (47). Dietary feeding of 8 mmol PEITC/kg diet to polyoma middle-T antigen transgenic mice resulted in smaller mammary cancer lesions, although there was no effect on lung metastasis or survival (48). Feeding of a diet supplemented with 0.05% PEITC alone or 0.025% PEITC in combination with 1% curcumin, a constituent of turmeric, significantly decreased incidence of prostate tumor in transgenic adenocarcinoma of mouse prostate (TRAMP) mice (49).

Recent studies from our laboratory have revealed that administration of 3 mmol PEITC/kg diet decreases incidence as well as burden (affected area) of poorly differentiated tumors in the dorsolateral prostate of TRAMP mice (50). Dietary administration of 3 mmol BITC/kg diet for 25 weeks markedly suppressed the incidence and/or burden of mammary hyperplasia and carcinoma in female MMTV-neu transgenic mice without causing weight loss or affecting neu protein level (51). The BITC-mediated prevention of mammary carcinogenesis in MMTV-neu mice was shown to be associated with T-cell infiltration and induction of E-cadherin (51). Mammary cancer in MMTV-neu mice is also suppressed by dietary administration of 3 mmol PEITC/kg diet (S.V. Singh et al., unpublished results). Long-term administration of SFN in the diet resulted in suppression of tumor development in Apc\textsuperscript{min} mice (52). Dietary administration of SFN (300 and 600 ppm) for 3 weeks to Apc\textsuperscript{min} mice resulted in suppression of polyps in the small intestine in a dose-dependent manner (53). Oral gavage of 6 μmol SFN thrice per week beginning at 6 weeks of age significantly inhibited prostate intraepithelial neoplasia and pulmonary metastasis in TRAMP mice (54). Consistent with these results, 8-week-old TRAMP mice fed with 240 mg of broccoli sprouts/mouse/day exhibited a significant retardation of prostate tumor growth in another study (55).

**Table II.** Chemopreventive efficacy of isothiocyanates (ITCs) in transgenic mouse models

<table>
<thead>
<tr>
<th>Agent</th>
<th>Transgenic mouse model</th>
<th>Experimental protocol</th>
<th>Effect</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEITC</td>
<td>Apc\textsuperscript{Min} mouse model of gastrointestinal cancer</td>
<td>Dietary administration of 0.05% PEITC</td>
<td>Inhibition of intestinal polyp development and reduced intestinal tumor size</td>
<td>(47)</td>
</tr>
<tr>
<td></td>
<td>Polymyoma middle-T antigen (PyMT) transgenic mouse model of breast cancer</td>
<td>Dietary feeding of 8 mmol PEITC/kg</td>
<td>Reduced size of mammary cancer lesions</td>
<td>(48)</td>
</tr>
<tr>
<td></td>
<td>Transgenic adenocarcinoma of mouse prostate (TRAMP) model of prostate cancer</td>
<td>Dietary feeding of 0.05% PEITC alone or 0.025% PEITC + 1% curcumin</td>
<td>Inhibition of prostate tumor incidence</td>
<td>(49)</td>
</tr>
<tr>
<td></td>
<td>Transgenic adenocarcinoma of mouse prostate (TRAMP) model of prostate cancer</td>
<td>Dietary administration of 3 mmol BITC/kg</td>
<td>Inhibition of incidence and burden of poorly-differentiated prostate tumor</td>
<td>(50)</td>
</tr>
<tr>
<td>BITC</td>
<td>MMTV-neu transgenic mouse model of breast cancer</td>
<td>Dietary administration of 3 mmol BITC/kg</td>
<td>Suppression of incidence and/or burden of hyperplasia and carcinoma</td>
<td>(51)</td>
</tr>
<tr>
<td>SFN</td>
<td>Apc\textsuperscript{Min} mouse model of gastrointestinal cancer</td>
<td>Dietary feeding of 6 μmol SFN/day</td>
<td>Suppression of polyp formation</td>
<td>(52)</td>
</tr>
<tr>
<td></td>
<td>Apc\textsuperscript{Min} mouse model of gastrointestinal cancer</td>
<td>Dietary feeding of 300 or 600 ppm of SFN/day</td>
<td>Suppression of polyps in the small intestine</td>
<td>(53)</td>
</tr>
<tr>
<td></td>
<td>Transgenic adenocarcinoma of mouse prostate (TRAMP) model of prostate cancer</td>
<td>Oral gavage of 6 μmol SFN thrice a week</td>
<td>Inhibition of prostate intraepithelial neoplasia and pulmonary metastasis</td>
<td>(54)</td>
</tr>
<tr>
<td></td>
<td>Transgenic adenocarcinoma of mouse prostate (TRAMP) model of prostate cancer</td>
<td>Feeding with 240 mg broccoli sprouts/mouse/day</td>
<td>Inhibition of prostate tumor growth</td>
<td>(55)</td>
</tr>
</tbody>
</table>

Abbreviations: PEITC, Phenethyl isothiocyanate; BITC, Benzyl isothiocyanate; SFN, Sulforaphane
been demonstrated (75). Interestingly some ITCs selectively deplete
Lack of p53 involvement in apoptosis induction by BITC has also
later shown to cause apoptosis in p53-deficient cancer cells (74).

It has been shown that PEITC induces apoptosis in both normal and cancer cell lines, whereas androgen-responsive LNCaP prostate cancer cells exposed to SFN were arrested in both S and G2/M phases of the cell cycle (68). Mechanisms by which ITCs cause cell-cycle arrest have been reviewed elsewhere (4–6). As an example, using PC-3 cells as a model we demonstrated important contribution of checkpoint kinase-2 activation leading to phosphorylation and cytoplasmic sequestration of cell division cycle 25C in SFN-mediated G2/M phase cell-cycle arrest (67).

One of the unique properties of ITCs is their ability to selectively cause apoptosis in cancer cells. Differential sensitivity of cancer cells versus normal epithelial cells to apoptosis induction has been noted for PEITC (4,69), BITC (5,62) and SFN (70). Research over the past decade reveals that the molecular circuitry of apoptosis induction by ITCs is complex and utilizes a wide range of molecular mechanisms, including alterations in Bcl-2 family protein expression, activation of mitogen-activated protein kinases, suppression of oncogenic signaling pathways and activation of caspases (reviewed in refs. 4–6,71).

Yu et al. (72) were the first to show apoptosis induction by PEITC in HeLa cells. During the same time period, Huang et al. (73) used mouse embryonic fibroblasts to demonstrate a critical role for p53 in regulation of PEITC-induced apoptosis. This association was found to be unique to the mouse embryonic fibroblasts because PEITC was later shown to cause apoptosis in p53-deficient cancer cells (74). Lack of p53 involvement in apoptosis induction by BITC has also been demonstrated (75). Interestingly some ITCs selectively deplete mutant p53, but not the wild-type p53, via a transcription-independent mechanism (76). Direct p53 binding followed by conformational change is implicated in depletion of mutant p53 by some ITCs (76).

Mechanistic complexity of apoptosis induction by PEITC, BITC and SFN has been reviewed previously (4–6,71) but production of reactive oxygen species appears to be a common link in apoptosis induction by PEITC, BITC and SFN (77–82). Interestingly, normal cells are resistant to ROS production by ITCs (78,81). The mechanism of ROS production and signal transduction downstream of ROS production in execution of apoptosis by PEITC, BITC and SFN involves inhibition of mitochondrial respiratory chain and activation of multidomain proapoptotic protein Bax, respectively (80–82). The mechanism underlying differential sensitivity of cancer cells and normal cells to apoptosis induction by ITCs is still unclear but PEITC treatment has been shown to differentially alter expression of oxidative stress and antioxidant defense genes in PC-3 (a prostate cancer cell line) versus PrEC cells (a normal prostate epithelial cell line) (83). A role for the adapter protein p66Shc has also been established in ROS production and apoptosis induction by PEITC as well as SFN (84,85).

Neoangiogenesis is critical not only for tumor growth but also for metastatic spread (86). Several groups have thoroughly investigated anti-angiogenic effect of ITCs. For example, PEITC treatment decreased expression of vascular endothelial growth factor and inhibited capillary-like tube structure formation (a measure of neoangiogenesis) and migration in human umbilical vein endothelial cells (87). Furthermore, the PEITC treatment inhibited angiogenesis ex vivo as revealed by chicken egg chorioallantoic membrane assay (87). PEITC is an effective inhibitor of hypoxia inducible factor (88),
a proangiogenic transcription factor. Because angiogenesis plays an important role in metastasis, a previous study from our group determined the effect of PEITC administration on incidence and multiplicity of pulmonary metastasis in TRAMP model (50). Overall incidence of pulmonary metastasis did not differ between the control and the PEITC-treated mice but the number of lung metastasis per mouse in the mice fed PEITC-supplemented diet was about 38% lower than that in the mice fed control diet (50). In MDA-MB-231 xenografts, analysis of the vasculature in the tumors from BITC-treated mice indicated smaller vessel area compared with control tumors based on immunohistochemistry for angiogenesis marker CD31 (89). The BITC-mediated inhibition of angiogenesis in vivo correlated with downregulation of vascular endothelial growth factor receptor 2 protein levels in the tumor (89). Oral BITC treatment induced hSFRP4 bin content, CD31 and vascular endothelial growth factor expression in vivo (90). The BITC-mediated inhibition of neoangiogenesis in rat aorta and chicken-chorioallantoic membrane models was also shown (91). The inhibitory effect of SFN on endothelial cell function essential for angiogenesis were shown using HMEC-1, an immortalized human microvascular endothelial cell line (92). The SFN treatment suppressed angiogenesis and disrupted endothelial mitotic progression and microtubule polymerization (93). Anti-angiogenic effect for ITCs has been reviewed by Caversaccio et al. (94). In summary, it is reasonable to conclude that inhibition of post-initiation cancer development by ITCs is probably achieved by suppression of multiple processes relevant to cancer progression.

Functional significance of autophagy induction by PEITC/ BITC versus SFN

Autophagy is an evolutionarily conserved process for bulk degradation of macromolecules including organelles (e.g. mitochondria) (95). Autophagy is considered a valid cancer chemotherapeutic agent (95,96). Our laboratory was the first to document autophagy induction by SFN in prostate cancer cells (97). Autophagy induction by SFN was since then confirmed by other investigators in different cellular systems (98,99). Even though autophagy induction is not unique to SFN as this process is activated upon treatment of cancer cells with PEITC (100) and BITC (101) and the autophagic response to all three agents is partially linked to ROS production (81,82,101), outcome of this cellular response is strikingly different for PEITC and BITC versus SFN (97,100,101). Autophagy serves to inhibit apoptosis induction by SFN by preventing release of cytochrome c from mitochondria to the cytosol (97). To the contrary, autophagy induction contributes to cell death by PEITC and BITC (100,101). Previous studies from our laboratory have also provided in vivo correlative evidence for autophagy induction by PEITC and BITC (50,100,101). Similar to apoptosis, normal epithelial cells are significantly more resistant to induction of autophagy by PEITC and BITC compared with cancer cells (100,101). Mechanism underlying autophagy induction by PEITC or SFN is still unresolved, but BITC-mediated autophagy is associated with increased acetylation of FoxO1 (101).

ITCs inhibit self-renewal of cancer stem cells

Evidence continues to accumulate to suggest that resistance of cancer stem cells to conventional therapy (e.g. chemotherapy, hormonal therapy, radiotherapy) is a major cause of disease recurrence (102,103). It was shown recently that SFN can suppress self-renewal of breast cancer stem cells characterized by a significant decrease in aldehyde dehydrogenase 1-positive cell population and reduction in the size and number of primary mammospheres (104). The SFN-mediated inhibition of self-renewal of breast cancer stem cells correlated with suppression of Wnt/β-catenin pathway (104). Furthermore, daily injection with 50mg/kg SFN for 2 weeks reduced aldehyde dehydrogenase 1-positive cells by >50% in a breast cancer xenograft model (104). Unpublished studies from our laboratory also indicate inhibitory effect of BITC on self-renewal of breast cancer stem cells (S.V. Singh, unpublished results). Efficacy of PEITC against cancer stem cells and that of BITC or SFN against cancer stem cells of other organs is yet to be determined.

BITC inhibits epithelial to mesenchymal transition in breast cancer cells

Using human breast cancer cells (MDA-MB-231 and MCF-7) as a model, we have demonstrated previously that BITC inhibits epithelial to mesenchymal transition (EMT) (105). The EMT is essential for normal physiological processes such as embryonic development, tissue remodeling and wound healing (106). During EMT, epithelial phenotype characterized by tight cell–cell junctions and polarity changes to a mesenchymal phenotype typified by disruption of the cell–cell contact with conversion to fibroblastic morphology and increased motility (106). The EMT is implicated in progression of cancers to invasive state (106). The BITC-mediated inhibition of EMT in breast cancer cells was characterized by upregulation of E-cadherin and downregulation of mesenchymal markers, including vimentin and fibronectin (105). Our observations of EMT inhibition by BITC have since been confirmed by other investigators (107). The mechanism by which BITC inhibits EMT is still unresolved, but the BITC-mediated growth retardation of MDA-MB-231 xenograft in vivo is associated with induction of E-cadherin and suppression of vimentin and fibronectin protein levels in the tumor (105). Studies are needed to determine if anti-EMT effect is unique to BITC.

Lack of target-specificity is probably beneficial for cancer chemoprevention by ITCs

Lack of target-specificity is a frequently voiced sentiment for naturally occurring chemopreventive agents, and ITCs are no exception to this potential criticism. In our view, ability to target multiple pathways is a desirable attribute for chemopreventive agents because pathogenesis of cancer is complex often characterized by deregulation of multiple checkpoints and activation of several oncogenic pathways. Agents selective against a single pathway/molecule may have limited clinical utility as exemplified by the estrogen receptor antagonists (1,2). An overall mechanistic model emerging from research over the past two decades stipulates that ITCs, including PEITC, BITC and SFN, have the ability to not only inhibit cancer initiation by decreasing carcinogen activation and/or increasing detoxification of the activated carcinogenic intermediates but also prevent post-initiation cancer development by affecting a variety of processes relevant to cancer progression. Alteration of carcinogen metabolism as a likely mechanism for the ITC-mediated inhibition of cancer initiation has been reviewed extensively elsewhere (71,108–110), but some of the notable mechanisms potentially contributing to post-initiation cancer chemoprevention by ITCs include: (i) inhibition of histone deacetylase (111); (ii) inhibition of oncogenic transcription factors (e.g. nuclear factor-κB, signal transducer and activator of transcription 3, androgen receptor and estrogen receptor-α) (61,112–116); (iii) protein binding (117) and (iv) inhibition of cap-dependent translation (118). However, relative contribution of these mechanisms to cancer chemoprevention by ITCs is hard to predict.

Even a subtle change in the ITC structure can have a profound impact on its activity

A potential misperception about ITCs is that they share common mechanism of action. On one hand, this argument has some validity considering most ITCs are inducers of phase 2 enzymes contributing to their pre-initiation chemopreventive effects (4,6,10,108). At the same time, examples exist to illustrate that even subtle difference in the ITC structure can translate into striking mechanistic divergence. For example, we have shown recently that apoptosis induction by PEITC is mediated by Bim in MCF-7 and MDA-MB-231 human breast cancer cells (119). Surprisingly, Bim is dispensable for proapoptotic response to BITC in the same cell lines (120). Autophagy is another example...
to highlight mechanistic differences between ITCs (97,100,101). Noticeable differences in efficacy of ITCs for prevention of chemically induced as well as spontaneous cancers in rodents have also been reported. For instance, SFN and PEITC seem to inhibit different stages of prostate cancer development in the TRAMP model (50,54). Although SFN treatment inhibits incidence of prostatic intraepithelial neoplasia and well-differentiated cancer (54), PEITC is an effective suppressor of poorly differentiated prostate cancer in TRAMP model (50). Interestingly, prostate cancer prevention by SFN in TRAMP model is associated with increased lytic activity of natural killer cells (54). On the other hand, PEITC administration has no effect on activity of natural killer cells (S.V.Singh, unpublished results).

**Biomarkers of ITC exposure/response**

Successful clinical realization of a chemopreventive strategy depends on systematic investigations beginning with identification of promising agents and characterization of their mechanisms of action to animal studies focusing not only on bioavailability, safety and efficacy assessments but also on discovery of biomarker(s) associated with exposure and response prior to translation in humans with a pilot biomarker modulation trial in a smaller cohort followed by larger trials with cancer incidence as the primary end point. Biomarker(s) of tissue exposure and/or response are critical for cancer chemopreventive agents because clinical trials with cancer incidence as the primary end point are expensive and laborious requiring years of follow-up and thousands of high-risk subjects. Recent studies have identified some biomarkers potentially useful in future clinical investigations of ITCs. Our own studies have utilized two-dimensional gel electrophoresis followed by mass spectrometry to identify plasma clusterin as a potential biomarker of PEITC exposure and possibly response in TRAMP model (50). Clusterin (also known as apolipoprotein J and testosterone-repressed prostate message-2) is a highly conserved protein expressed in a variety of tissues, secreted in blood, and involved in regulation of apoptosis, cell adhesion, cell-cycle, and DNA repair (121,122). Increased levels of clusterin have been reported in several malignancies including breast, colon, lung, and prostate cancer (121). Moreover, expression of clusterin correlated with Gleason score in prostate cancer patients (122). Future clinical trials will test whether clusterin is a viable biomarker to assess tissue exposure and/or response to PEITC. Stable reaction products with albumin and hemoglobin as biomarkers to monitor ITC exposure in humans have also been identified (123,124). For instance, blood samples collected from a normal healthy volunteer 1 day after ingestion of garden cress (60 g), watercress (100 g) and broccoli (300 g) revealed presence of clusterin from a normal healthy volunteer 1 day after ingestion of garden cress (123). Increased levels of clusterin have been reported in several malignancies including breast, colon, lung, and prostate cancer (121). Moreover, expression of clusterin correlated with Gleason score in prostate cancer patients (122). Future clinical trials will test whether clusterin is a viable biomarker to assess tissue exposure and/or response to PEITC. Stable reaction products with albumin and hemoglobin as biomarkers to monitor ITC exposure in humans have also been identified (123,124). For instance, blood samples collected from a normal healthy volunteer 1 day after ingestion of garden cress (60 g), watercress (100 g) and broccoli (300 g) revealed presence of clusterin from a normal healthy volunteer 1 day after ingestion of garden cress (123).

**ITCs are chemotherapeutic sensitizers**

Evidence exists to suggest that ITCs may act as sensitizers of chemotherapeutic agents. Sublethal doses of PEITC sensitized Fas-resistant T24 bladder carcinoma cell line and Bcl-2 overexpressing Jurkat T cells to Fas-mediated apoptosis (125). Inhibition of P-glycoprotein and multidrug-resistance protein 1-mediated efflux of daunomycin, which is a major mechanism of resistance for some anticancer agents, by PEITC has been described (126,127). The PEITC caused sensitization of PC-3 and HeLa cells to adriamycin and etoposide-induced apoptosis by downregulation of protein kinase C and inhibition of telomerase activity (128,129). The PEITC and BITC treatments resulted in sensitization of non-small cell lung cancer cell line NCI-H596 to cisplatin independent of cellular platinum accumulation or DNA platination (130). Studies from our laboratory have revealed that pharmacologic concentrations of PEITC augment Docetaxel-induced apoptosis in PC-3 and DU145 human prostate cancer cells in association with suppression of Bcl-2 and XIAP protein levels and induction of Bak and Bak (131). Pretreatment with BITC resulted in sensitization of BxPC-3 pancreatic cancer cells to gamma-radiation induced cell-cycle arrest and apoptosis due to inhibition of nuclear factor-κB and activation of p38 mitogen-activated protein kinase (132). The BITC treatment increased sensitivity of MIAPaCa-2 and PANC-1 pancreatic cancer cells to X-ray in association with increased apoptosis, suppression of X-linked inhibitor of apoptosis protein and increase in apoptosis protease activating factor-1 (133). The BITC treatment resulted in sensitization of a panel of pancreatic cancer cells to TRAIL-induced apoptosis due to dual activation of extrinsic and intrinsic pathways (134). The SFN potentiated effects of chemotherapeutic drugs (e.g. cisplatin) on inhibition of clonogenicity and spheroid formation and aldehyde dehydrogenase 1 activity along with Notch-1 and c-Rel expression in pancreatic and prostate cancer cells (135). The SFN and doxorubicin combination reversed resistance in mouse fibroblasts with p53<sup>53E220</sup> mutation (136).

The in vivo relevance of most of these predominantly cellular findings is still unclear, but we have shown previously that PEITC–Docetaxel combination is markedly more efficacious against PC-3 xenograft in vivo compared with PEITC or Docetaxel alone (131). The SFN and chemotherapy drug combination was most effective and totally abolished growth of cancer stem cell xenografts and tumor-initiating potential (135). Similar in vivo studies with other ITC-chemotherapy drugs are necessary to spark interest among clinicians to test such combinations in cancer patients.

**Some ITCs activate Notch signaling in cancer cells and normal epithelial cells**

Recent studies from our laboratory have demonstrated that PEITC treatment increases cleavage (activation) of Notch1 and Notch2 in prostate cancer cells leading to transcriptional activation of Notch (137). Notch pathway is implicated in tumorigenesis, maintenance of mesenchymal phenotype and self-renewal of cancer stem cells (138–140). The PEITC-mediated activation of Notch is not selective for cancer cells as normal epithelial cells (pRECs) are also sensitive to Notch1 and Notch2 activation by PEITC (137). However, Notch activation may be a double-edge sword in the context of cancer chemoprevention with these ITC compounds. On one hand, PEITC-induced apoptosis in LNCaP and PC-3 cells was attenuated by RNA interference of Notch2, but not Notch1 (137). On the other hand, inhibition of PC-3 and LNCaP cell migration resulting from PEITC exposure was significantly augmented by knockdown of Notch2 as well as pharmacological inhibition of Notch1 activation (137). Further studies are needed to determine whether Notch1 and Notch2 activation by PEITC is unique to prostate cancer cells, and if Notch activation affects cancer chemopreventive response to PEITC in vivo. Activation of Notch1, Notch2, and Notch4 upon treatment with BITC has been observed in human breast cancer cells (141). The BITC-mediated inhibition of breast cancer cell migration was significantly augmented by RNA interference of Notch2, but not Notch1 or Notch4 (141). Once again these observations underscore mechanistic differences between structurally related ITC compounds.

**miRNAs targeted by BITC**

The miRNA function as either oncogenes or tumor suppressor and can target multiple genes (142). Recent studies have shown that BITC treatment alters the expression of miRNA-221 and miRNA-375 to switch hyperproliferative cancer cells to a hypoproliferative state in pancreatic adenocarcinoma cells (143). The miRNA-221 and miRNA-375 are abnormally expressed in pancreatic cancer patients (144). Ectopic expression of miRNA-375 and silencing of miRNA-221 sensitized cells to antiproliferative effect of BITC (143). Additional work is needed to determine if other ITCs target miRNA as well as to identify other potential miRNA targeted by ITCs.

**Human studies are limited to raw cruciferous vegetables or their extracts**

Human studies on biological effects of pure ITC compounds are still lacking, but a few studies have attempted to determine the effects...
of raw cruciferous vegetables or their extracts on certain biological parameters (145–149). For example, consumption of 2 ounce (56.8 g) of watercress at each meal for 3 days was shown to inhibit oxidative metabolism of 4-(methylnitrosamo)-1-(3-pyridyl)-1-butanone in smokers (145). Consistent with cellular observations (118), phosphorylation of 4E-BP1 was significantly reduced 6 and 8 hours after ingestion of 80 g watercress in peripheral blood cells from four participants (146). Another randomized and placebo-controlled trial performed in Qidong, China, utilizing a beverage infused with 3-day-old broccoli sprouts showed an inverse association between excretion of diethiocarbamates and urinary aflatoxin-DNA adducts (148). Ingestion of 68 g of broccoli sprouts by humans resulted in a significant decrease in histone deacetylase activity in peripheral blood mononuclear cells (149).

Concluding remarks and future directions

Discovery of cancer chemopreventive potential of ITCs more than 30 years ago sparked tremendous research interest focusing on pharmacokinetic, efficacy, and mechanistic characterization of these compounds. Notably, emerging technologies and research tools (e.g. RNA interference, microarray, proteomics, etc.) have been appropriately utilized to study the mechanism by which ITCs may prevent cancer. Clinical investigation of ITCs for cancer chemoprevention seems more plausible today mainly because of knowledge acquired in the past few decades. However, a few lingering hurdles in clinical development of ITCs are noteworthy. First, formulations of pure ITCs suitable for clinical investigations are not yet available. Second, clinical trial designs must consider rapid clearance of ITCs as corresponding mercapturic acids; a single daily administration schedule may not be effective. Finally, the question of whether PEITC and BITC are promoters of bladder cancer requires further investigation because this may turn out to be a major obstacle in long-term usage of ITCs for cancer prevention in high-risk subjects.

Funding

The work cited from the Singh laboratory was supported by the US PHS grant RO1 CA101753, RO1 CA129347 and RO1 CA115498 awarded by the National Cancer Institute.

Acknowledgments

Contributions of the present (Eun-Ryeong Hahn, Su-Hyeong Kim, Anuradha Sehrawat, Marie L. Antony, Koizue Sakao, Julie A Arlotti) and past members (Sanjay K. Srivastava, Karen L. Lew, Dong Xiao, Yan Zeng, Sunga Choi, Anna Herman-Antosiewicz, Ajay Bommarmedy) of the Singh laboratory to the pre-clinical studies cited in this article are greatly appreciated.

Conflict of Interest: The authors have no conflict of interest.

References


Isothiocyanates and cancer chemoprevention


76. Powolny, A.A. et al. (2010) Differential response of normal (PrEC) and cancerous human prostate cells (PC-3) to phenethyl isothiocyanate-mediated
Isothiocyanates and cancer chemoprevention


Received April 27, 2012; revised June 13, 2012; accepted June 19, 2012